Arcturus Therapeutics
ARCT
170 hedge funds and large institutions have $640M invested in Arcturus Therapeutics in 2024 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 45 increasing their positions, 65 reducing their positions, and 40 closing their positions.
121% more call options, than puts
Call options by funds: $9.61M | Put options by funds: $4.35M
3.57% less ownership
Funds ownership: 101.13% → 97.57% (-3.6%)
5% less funds holding
Funds holding: 179 → 170 (-9)
15% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 40
30% less capital invested
Capital invested by funds: $919M → $640M (-$279M)
31% less repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 65
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$12M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
+$8.69M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$8.69M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$8.35M |
| 5 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$7.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$15.2M |
| 2 |
State Street
Boston,
Massachusetts
|
-$13.2M |
| 3 |
GLA
Great Lakes Advisors
Chicago,
Illinois
|
-$7.1M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$5.63M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$4.86M |
ARCT Hedge Fund Activity: Q2 2024 in Review
170 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q2 2024, worth a combined $640M — down 30% from $919M a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of ARCT and 34 opened new positions — a net loss of 6 holders — while 65 trimmed existing stakes and 45 added.
The largest buyer was Millennium Management, adding an estimated $12M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $15.2M sold.
- 170 institutional investors held Arcturus Therapeutics (ARCT) as of Q2 2024, down from 179 in Q1 2024.
- Funds reported $640M of Arcturus Therapeutics stock for Q2 2024, down 30% quarter-over-quarter.
- 34 funds opened new Arcturus Therapeutics positions in Q2 2024 and 40 closed out, a net change of -6 holders.
- The largest Arcturus Therapeutics buyer in Q2 2024 was Millennium Management, an estimated $12M added.
- The largest Arcturus Therapeutics seller in Q2 2024 was Adage Capital Partners, an estimated $15.2M sold.
Based on aggregated 13F filings for Q2 2024.